

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1. (Previously Presented) A delivery system for pharmaceutical agents wherein said system comprises liposomes which comprise in their internal compartment a pharmaceutical agent and which have linked to their external surface the cell adhesion molecule NCAM or a fragment thereof, wherein said pharmaceutical agent is DNA and said delivery system comprises a DNA integrase activity or a molecule encoding such a DNA integrase activity.
2. (Original) The delivery system of claim 1, wherein said NCAM fragment comprises IG loop domains I, II and III.
3. (Previously Presented) The delivery system according to claim 1, wherein said cell adhesion molecule is linked to said external surface of said liposomes via a transmembrane domain or a hydrophobic anchor molecule.
4. Canceled
5. (Previously Presented) The delivery system according to claim 1, wherein said DNA is operably linked to a gene expression construct.
6. (Previously Presented) The delivery system according to claim 5, wherein said DNA is cDNA which is operably linked to a gene expression construct.
- 7-8. Canceled
9. (Previously Presented) The delivery system according to claim 5, wherein said delivery system comprises a DNA compacting agent.

10. (Previously Presented) The delivery system according to claim 6, wherein said delivery system comprises a DNA compacting agent.
11. (Previously Presented) The delivery system according to claim 29, wherein said delivery system comprises a DNA compacting agent.
12. Canceled
13. (Previously Presented) The delivery system according to claim 9, wherein said DNA compacting agent is a reversibly cross-linkable cation.
14. (Previously Presented) The delivery system according to claim 10, wherein said DNA compacting agent is a reversibly crosslinkable cation.
15. (Previously Presented) The delivery system according to claim 11, wherein said DNA compacting agent is a reversibly crosslinkable cation.
16. Canceled
17. (Previously Presented) The delivery system according to claim 13, wherein said reversible cross-link is a thio bridge.
18. (Previously Presented) The delivery system according to claim 14, wherein said reversible cross-link is a thio bridge.
19. (Previously Presented) The delivery system according to claim 15, wherein said reversible cross-link is a thio bridge.
20. Canceled

21. (Currently Amended) The delivery system according to anyone of claims 5, 6, 11 ~~9-11, 15 13-15, 17-19~~ or 29, wherein said delivery system comprises a chemical inclusion and/or a biological inclusion for the breaching of the endosomal barrier.

22. (Currently Amended) The delivery system according to anyone of claims 5, 6, 11 ~~9-11, 15 13-15, 17-19, 21~~ or 29, wherein said delivery system comprises a nuclear localisation signal.

23. (Previously Presented) The delivery system according to claim 22, wherein said nuclear localisation signal comprises PNA linked peptides or PDA linked ligands.

24. (Currently Amended) The delivery system according to anyone of claims 5, 6, 11 ~~9-11, 15 13-15, 17-19, 21-23~~ or 29, wherein said delivery system comprises an anti-apoptotic activity.

25. (Previously Presented) The delivery system according to claim 24, wherein said anti-apoptotic activity is selected from the group consisting of Bcl-2, a small interfering RNA directed against Bax, a peptide comprising caspase inhibitor sequences, preferably Bcl XL.

26. Canceled

27. (Previously Presented) The delivery system according to claim 1, wherein said integrase is the integrase of phi C31 bacteriophage.

28. (Currently Amended) A pharmaceutical composition comprising a delivery system according to any one of claims 5, 6, 11 ~~9-11, 15 13-15, 17-19, 21-25, 27~~ or 29.

29. (Previously Presented) A delivery system for pharmaceutical agents wherein said system comprises liposomes which comprise in their internal compartment a pharmaceutical

Appln. No.: 10/520,909

Amendment dated April 28, 2009

Reply to Office Action of October 28, 2008

agent and which have linked to their external surface the cell adhesion molecule NCAM or a fragment thereof, wherein said delivery system comprises DNA that encodes the human dystrophin protein.